(Alliance News) - GSK PLC on Thursday said the prefilled syringe version of its vaccine Shingrix has been approved for use in the US for the prevention of shingles.

London: GSK plc has received approval from the US Food and Drug Administration (FDA) for a prefilled syringe presentation of Shingrix (GSK's Recombinant Zoster Vaccine or RZV) for the prevention ...

Prefilled syringe presentation offers a convenient administration option to healthcare professionals·         An estimated one million people develop shingles in the US each year[1]GSK plc ...

GSK PLC closed 16.45% short of its 52-week high of £16.79, which the company reached on September 9th.

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

GSK PLC closed 15.32% short of its 52-week high of £16.79, which the company reached on September 9th.

London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend ...

FDA reviewers said in briefing documents that the benefit-risk profile of the drug for the treatment of multiple myeloma “remains unclear.” ...

GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...

GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

PDUFA date nears for GSK plc’s Blenrep (belantamab mafodotin), the U.S. FDA’s Oncologic Drugs Advisory Committee will decide July 17 on whether available data justify the return to market of the ...